Starling Oncology Inc provides oncology care services in community settings. Its services include cancer diagnosis and treatment, clinical trials, transfusion services, and other oncology care delivery models for patients.
Last trade$3.40
Day change-$0.14 (-3.95%)
Day range$3.39 – $3.71
Volume2,659,371
Market cap$361M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$361.05M
Price / earnings
—
Price / book
-9.67×
Price / sales
0.58×
EV / sales
0.65×
EV / EBITDA
-27.87×
Profitability
Earnings per share
-$0.34
Return on assets
-18.35%
Return on equity
92.24%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-2.08×
Current ratio
1.11×
Quick ratio
0.82×
Cash ratio
0.3×
Cash flow
Price / cash flow
15.63×
Price / free cash flow
19.18×
Free cash flow
$18.83M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for STLN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Revenue
$169.77M
Cost of revenue
$139.1M
Gross profit
$30.67M
Selling, general and administrative
$32.13M
Research and development
$0
Total operating expenses
$33.65M
Operating income
-$2.98M
Interest expense
-$1.82M
Income before taxes
-$15.75M
Income taxes
$0
Net income
-$15.75M
Net income attributable to common shareholders
-$15.75M
EBITDA
-$1.46M
Basic earnings per share
-$0.13
Diluted earnings per share
-$0.13
Recent news
Company coverage with links to the original publishers.
Starling Oncology reported a Q3 loss of $0.13 per share, missing EPS expectations of $0.07 loss by 85.71%, though the company beat revenue estimates with $169.77 million versus consensus of $168.41 million. The stock has gained 94.9% year-to-date but received a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Ultragenyx (RARE) reported a quarterly loss of $1.16 per share, slightly missing the consensus estimate of $1.15, with revenues of $173 million falling 6.11% short of expectations. Despite underperforming the market by 29.1% year-to-date, the stock maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revisions. The Medical - Biomedical and Genetics industry ranks in the top 44% of sectors.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.